IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ)verified

IRLAB-A.ST

Price:

$1.94

Market Cap:

$164.62M

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden...[Read more]

Industry

Biotechnology

IPO Date

2017-02-28

Stock Exchange

STO

Ticker

IRLAB-A.ST

The PE Ratio as of December 2025 (TTM) for IRLAB Therapeutics AB (publ) (IRLAB-A.ST) is -1.36

According to IRLAB Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -1.36. This represents a change of -83.76% compared to the average of -8.38 of the last 4 quarters.

IRLAB Therapeutics AB (publ) (IRLAB-A.ST) Historical PE Ratio (quarterly & annually)

How has IRLAB-A.ST PE Ratio performed in the past?

The mean historical PE Ratio of IRLAB Therapeutics AB (publ) over the last ten years is -10.00. The current -1.36 PE Ratio has changed 1.26% with respect to the historical average. Over the past ten years (40 quarters), IRLAB-A.ST's PE Ratio was at its highest in in the September 2021 quarter at 4.87. The PE Ratio was at its lowest in in the September 2018 quarter at -42.93.

Quarterly (TTM)
Annual

Average

-10.00

Median

-16.24

Minimum

-32.20

Maximum

43.97

IRLAB Therapeutics AB (publ) (IRLAB-A.ST) PE Ratio by Quarter and Year

Discovering the peaks and valleys of IRLAB Therapeutics AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 161.34%

Maximum Annual PE Ratio = 43.97

Minimum Annual Increase = -301.69%

Minimum Annual PE Ratio = -32.20

Quarterly (TTM)
Annual
YearPE RatioChange
2024-6.71161.34%
2023-2.57-85.23%
2022-17.38-139.53%
202143.97-301.69%
2020-21.8041.34%
2019-15.42-52.10%
2018-32.2088.86%
2017-17.05143.38%
2016-7.01-70.58%
2015-23.81-126.26%

IRLAB Therapeutics AB (publ) (IRLAB-A.ST) Average PE Ratio

How has IRLAB-A.ST PE Ratio performed in the past?

The current PE Ratio of IRLAB Therapeutics AB (publ) (IRLAB-A.ST) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-8.89

5-year avg

-0.90

10-year avg

-10.00

IRLAB Therapeutics AB (publ) (IRLAB-A.ST) PE Ratio vs. Peers

How is IRLAB-A.ST’s PE Ratio compared to its peers?

IRLAB Therapeutics AB (publ)’s PE Ratio is greater than Lipum AB (publ) (-4.04), greater than Isofol Medical AB (publ) (-3.43), greater than Bio-Works Technologies AB (publ) (-6.10), less than Karolinska Development AB (publ) (-0.75), greater than Initiator Pharma A/S (-12.40), greater than Annexin Pharmaceuticals AB (publ) (-3.44), less than Xbrane Biopharma AB (publ) (2.10), greater than Alzinova AB (publ) (-6.36), greater than Active Biotech AB (publ) (-1.53), greater than Clinical Laserthermia Systems AB (publ) (-4.81),

Build a custom stock screener for IRLAB Therapeutics AB (publ) (IRLAB-A.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IRLAB Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

IRLAB Therapeutics AB (publ) (IRLAB-A.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like IRLAB Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is IRLAB Therapeutics AB (publ)'s PE Ratio?

How is the PE Ratio calculated for IRLAB Therapeutics AB (publ) (IRLAB-A.ST)?

What is the highest PE Ratio for IRLAB Therapeutics AB (publ) (IRLAB-A.ST)?

What is the 3-year average PE Ratio for IRLAB Therapeutics AB (publ) (IRLAB-A.ST)?

What is the 5-year average PE Ratio for IRLAB Therapeutics AB (publ) (IRLAB-A.ST)?

How does the current PE Ratio for IRLAB Therapeutics AB (publ) (IRLAB-A.ST) compare to its historical average?